Abstract：Objective To evaluate the therapeutic effect and treatment cost of recombinant human interferon α-1b on acute bronchiolitis in infants.Methods In this randomized and controlled clinical study, 70 children with acute bronchiolitis were divided into the study group and the control group with 35 cases each. The study group received recombinant human interferon α-1b [1 μg/(kg·d), 1 time/d, intramuscular injection] in addition to the conventional treatment. The control group received 50 ml saline and ribavirin [15 mg/(kg·d),twice, intravenous infusion] in addition to the conventional treatment. The total efficacy of the treatment on the two groups was compared. Coughing, wheezing, lung wheezes, crackles and days of hospitalization of the two groups were observed, and their treatment costs were statistically analyzed.Results The treatment efficacy in the study group was significantly higher than in the control group,with 97.2% and 82.8% respectively(χ2=19.78,P<0.05).All patients were cured. Hospitalization days were 4.09±1.21 and 7.54±1.59 in the study group and the controll group,respectively,with statistical significant difference. The disappearance time of symptoms and signs was significantly shorter and the treatment cost was significantly lower in the study group than in the control group (t=6.79,P<0.01).Conclusions Using recombinant human interferon α-1b as treatment of acute bronchiolitis can significantly improve the therapeutic effect and reduce the treatment cost.
Pelleier A J, Mansbach J M, Camargo C A. Direct medical costs of brochiolitis hospitalizations in the United States [J]. Pediatrics, 2006, 118(6): 2418-2423.
[2]
Hall C B. Respiratory syncytial virus and parainfluenza virus [J]. N Engl J Med, 2001, 344(25): 1917-1928.
2016, Vol. 27 
